Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

Gynecologic Oncology

Volumn 76, Issue 2, 2000, Pages 204-207

  Schilder, Russell J ^a   Blessing, John A ^b   Morgan, Mark ^c   Mangan, Charles E ^d   Rader, Janet S ^e  

^a FOX CHASE CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

EID: 0033959650     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5671     Document Type: Article

References (24)

1. Landis S H, Murray T, Bolden S, Wingo P A. Cancer statistics, 1998. CA Cancer J Clin. 48:1998;6-29.
2. Thigpen J T, Vance R B, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol. 22:1995;67-75.
3. Perez C A, Kurman R J, Stehman F B, Thigpen J T. Uterine Cervix. Hoskins W J, Perez C A, Young R C. Principles and Practice of Gynecologic Oncology. 1992;591-662 Lippincott, Philadelphia.
4. DeLong, D, C, Hertel, L, W, Tang, J, Kroin, J, S, Wilson, J, D, Terry, J, Lavender, J, F, Antiviral activity of 2′,2′-difluorodeoxycytidine, Proc Ann Meet Am Soc Microbiol, Washington, DC, March 24-28, 1986.
5. Huang P, Plunkett W. Induction of apoptosis by gemcitabine. Semin Oncol. 22:1995;19-25.
6. Hertel L W, Boder G B, Kroin J S, Rinzel S M, Poore G A, Todd G C, Grindey G B. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res. 50:1990;4417-4422.
7. Lawrence T S, Eisbruch A, Shewach D S. Gemcitabine-mediated radiosensitization. Semin Oncol. 24:1997;S7-24-S7-28.
8. Abbruzzese J L, Grunewald R, Weeks E A, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber M N. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 9:1991;491-498.
9. Pollera C F, Ceribelli A, Crecco M, Sabino F, Calabresi F. Weekly gemcitabine: a phase I study with short and prolonged infusion schedules. Proc Am Clin Oncol. 11:1992;127.
10. Brown T, O'Rourke T, Burris H, Kuhn J, Tarasoff P, Cagnola J, Rodriguez G, Von Hoff D. A phase I trial of gemcitabine (LY 188011) administered intravenously every two weeks. Proc Am Soc Clin Oncol. 10:1991;115.
11. Tanis B, Clavel M, Guastalla J, Osborne D, Quik R, McDaniel C, Pinedo H, Vermorkon J. Phase I study of gemcitabine (difluorodeoxycytidine; dFdC; LY188011) administered in a two weekly schedule. Proc Am Assoc Cancer Res. 31:1990;207.
12. Poplin E, Redmond B, Flaherty L, Wozniak A, Valdivieso M, Baker L. Difluorodeoxycytidine (dFdC): a phase I study. Proc Am Assoc Cancer Res. 30:1989;282.
13. O'Rourke T, Brown T, Havlin K, Kuhn J, Craig J, Boldt D, Burris H, Hamilton M, Sattarlee W, Tarassoff P, Von Hoff D. Phase I trial and immunologic assessment of difluorodeoxycytidine (LY188011). Proc Am Soc Clin Oncol. 8:1989;82.
14. Anderson H, Lund B, Thatcher N, Walling J, Hensen H H. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol. 12:1994;1821-1826.
15. Abratt R P, Bezwoda W R, Falkson G, Goedhals L, Hacking D, Rugg, TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol. 12:1994;1535-1540.
16. Carmichael J, Possinger K, Phillip P, Beyldrch M, Kerr H, Walling J, Harris A L. Difluorodeoxycytidine (gemcitabine): a phase II study in patients with advanced breast cancer. Proc Am Soc Clin Oncol. 12:1993;64.
17. Lund B, Hansen O P, Theilade K, Hansen M, Jeijt J P. Phase II study of gemcitabine in previously platinum treated ovarian cancer (OC). Proc Am Soc Clin Oncol. 12:1993;262.
18. Shapiro J D, Millward M J, Rischin D, Michael M, Walcher V, Francis P A, Toner G C. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 63:1996;89-93.
19. Burris H A, Moore M J, Andersen J, Green M R, Rothenberg M L, Modiano M R, Cripps M C, Portenoy R K, Storniolo A M, Tarassoff P, Nelson R, Dorr F A, Stephens C D, Von Hoff D D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 15:1997;2403-2413.
20. Omura G A, Blessing J A, Vacarello L, Berman M L, Clarke-Pearson D L, Mutch D G, Anderson B. Randomized trial of cisplatin versus cisplatin plus mitolactol (dibromdulcitol) versus cisplatin plus ifosfamide in advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 15:1997;165-171.
21. Crinò L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, Altavilla G, Incoronato P, Trippetti M, Mosconi A M, Santucci A, Sorbolini S, Oliva C, Tonato M. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 15:1997;297-303.
22. Nagourney R A, Link J, Kunkel L, Evans S. Phase II trial of cisplatin (Cddp) and gemcitabine (dfdc) in heavily pretreated breast cancer. Proc Am Soc Clin Oncol. 17:1998;161a.
23. Rose P G, Bundy B N, Thigpen J T, Deppe G, Maiman M, Clarke-Pearson D. Concomitant cisplatin-based chemoradiation improves progression-free and overall survival in advanced cervical cancer: results of a randomized Gynecologic Oncology Group study. New Engl J Med. 340:1999;1144-1153.
24. Thomas H, McCormack M, Singer J. A phase IB study of gemcitabine (GEM) and concurrent radiotherapy (RT) in advanced carcinoma of the cervix. Proc Am Soc Clin Oncol. 17:1998;376a.